BACKGROUND Eukaryotic cells can respond to diverse stimuli by converging at serine-51 phosphorylation on eukaryotic initiation factor 2 alpha (eIF2a) and activate the integrated stress response (ISR). This is a key step in translational control and must be tightly regulated; however, persistent eIF2a phosphorylation is observed in mouse and human atheroma.
translational control, eIF2a phosphorylation must be tightly regulated through dephosphorylation by the protein phosphatase-1 (PP1). In prolonged or severe stress, however, ISR can revert to a cell death program (1, 2) .
Endoplasmic reticulum (ER) stress is a trigger for ISR. Unfolded proteins are sensed by the ER-resident eIF2a kinase, protein kinase RNA-activated-like ER kinase (PERK), and trigger eIF2a phosphorylation. This homeostatic pathway is hyperactivated in obesity and dyslipidemia (2) (3) (4) . Evidently, reducing ER stress in mice reduces insulin resistance, obesity, and atherosclerosis (5) (6) (7) (8) .
ER stress is induced by saturated fatty acids (SFA), which are thought to promote cardiovascular diseases (CVD) (9) (10) (11) . Replacing 5% of the energy intake from SFA with an equivalent intake of monounsaturated fatty acids or polyunsaturated fatty acids is associated with a reduced risk (15% and 25%, respectively) of CVD (12) . A causal relationship between SFA intake and CVD risk was demonstrated in nonhuman primates (11) .
Other studies have challenged SFA's role in human CVD, and the molecular mechanisms of SFA-induced inflammation in atherosclerosis are not completely understood (10) .
Increased cellular lipid influx negatively impacts organelles leading to ER and mitochondrial stress, often intertwined in obesity (13) . Organelle stress is causally associated with inflammation and atherosclerosis (14) .
For example, organelle stress activates the Nod-like receptor family, pyrin domaincontaining protein-3 (NLRP3) inflammasome, leading to interleukin (IL)-1b and IL-18 secretion (7, 15, 16) . IL-1b is elevated in plaques and serum during dyslipidemia and drives atherosclerosis (7, (17) (18) (19) .
Persistent ISR activation, as evident by eIF2a and PERK phosphorylation, is observed in atheroma (8) .
PERK promotes foam cell formation, whereas CHOP deletion in mice reduces atherosclerosis (5, 6, 8, 20) .
The circumstantial evidence thus suggests that PERKinduced ISR may aggravate atherosclerosis, but can intercepting this homeostatic pathway in a chronic disease provide therapeutic gains? Using small molecules and genetic approaches to modulate multiple ISR nodes, we show lipid-activated PERK induces mitochondrial Lon protease-1 (LONP1). LONP1 degrades phosphatase tensin homolog-induced kinase-1 (PINK1) to suppress mitophagy, thus drives mitochondrial reactive oxygen species (mtROS) production and robust inflammasome activation in lipidstressed macrophages. Finally, ISR inhibition in vivo can suppress hyperlipidemia-induced inflammation and reduce atherosclerosis progression in mice.
METHODS
GENERAL STUDY DESIGN. Three or more independent replicates were performed for cell-based experiments. Mice were randomly assigned to independent cohorts, and data analysis was performed blind. The only elimination criteria used for mouse studies was based on health. Noted differences in mouse numbers (en face aorta and plaque analysis) is related to technical problems that occurred during sampling before analysis. MICE STUDIES AND TREATMENTS. C57BL/ 6.129P2-Apoe tm1Unc /J mice (Apoe À/À mice; received from Jackson Laboratory, Bar Harbor, Maine, and created by Nabuyo Maeda, University of North Carolina), and C57BL/6.129S4-Prkn tm1Shn /J (parkin À/À mice; received from Jackson Laboratory and created by Jie Shen, Harvard Medical School) and C57BL/ 6-eIF2ak3 tm2201(G646N,M886A)Arte mice (PERK_ASKA [ATP-analog sensitive kinase allele] mice; received from J.R. Lipford at Amgen, Thousand Oaks, California, and created by Taconic Artemis, Cologne, Germany); G646N/M886A mutations were introduced by Cre-Lox system and bred with Apoe À/À . Apoe À/À mice were injected with GSK2606414 (30 mg/kg/day; Atomole Scientific, Wuhan, China) or trans-ISRIB ( 
RESULTS

ISR REGULATES LIPID-INDUCED INFLAMMASOME
ACTIVATION. Lipid stress leads to eIF2a and PERK phosphorylation in macrophages and plaques (5, 9, 20) . Here, we sought to understand the contri- Additionally, we took advantage of the ATP analog sensitive kinase allele (ASKA) of PERK to specifically qRT-PCR ¼ quantitative reverse transcription polymerase chain reaction; other abbreviations as in Figure 1 .
Onat et al. Lipid-Induced Integrated Stress Response modulate PERK's kinase activity (22) . The ASKA approach involves a conserved (gatekeeper) amino acid mutation in the deep, hydrophobic ATP-binding kinase pocket, which unblocks access to bulky ATP analogs (23) . The M886A mutation on PERK confers the ability to use ATP analogs with bulky alkyl groups (22) . To prevent an unstable kinase (24) , the PERK_ASKA mice were designed with a second sta- Figure 2C ). ISRIB caused a small reduction in lipid-induced NLRP3 mRNA and unexpectedly in pro-IL-1b (Online Figure 2D ), but ATF4 knockdown did not impact pro-Il-1b mRNA (Online Figure 2E ). Collectively, these findings demonstrate that interrupting ISR signaling can profoundly block lipid-induced inflammasome activation. implicating LONP1 in Parkin-dependent mitophagy (30) . Mitophagy counteracts mtROS and inflammasome activation by lipids (16) . We asked whether LONP1 plays a role in SFA-induced mtROS production and inflammasome activation. Indeed, PA induced LONP1 expression ( Figure 3B ), which was significantly blocked by GSK2606414 ( Figure 3B ). Sephin1, on the other hand, induced LONP1 and prevented PERK inhibitor's ability to suppress LONP1 ( Figure 3B ). As expected, ISRIB significantly suppressed LONP1
( Figure 3B ). PERK or ATF4 knockdown also blocked LONP1 induction by lipids ( Figure 3B ) Onat et al.
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Lipid-Induced Integrated Stress Response b-actin. (F-H) LPS-primed, PA-stimulated BMDM were (F) transfected with LONP1 siRNA, and mtROS was measured with MitoSOX kit, or (G) transfected with LONP1 siRNA and supernatants were analyzed with IL-1b ELISA, whereas protein lysates were analyzed by Western blotting using antibodies against caspase-1 (p45 and p10), b-actin, and IL-1b, and total RNA was analyzed by qRT-PCR for LONP1 and GAPDH mRNA, or (H) treated with 1 mmol/l CDDO and supernatants were analyzed with IL-1b ELISA, whereas protein lysates were analyzed by Western blotting using antibodies against caspase-1 (p45 and p10), b-actin, and IL-1b, or (I) transfected with PINK1 siRNA and/or treated with GSK2606414 (2 mmol/l); the conditioned medium was analyzed by IL-1b ELISA or Western blotting using antibodies against caspase-1 (p10) and IL-1b, whereas total RNA was analyzed by qRT-PCR for PINK1 and GAPDH mRNA. (J) LPS-primed Parkin À/À or WT BMDM were treated with PA and GSK2606414 (2 mmol/l) or CDDO (1 to 2 mmol/l); conditioned cell medium was analyzed with IL-1b ELISA or by Western blotting using antibodies against caspase-1 (p45 and p10), b-actin, and IL-1b. Western blots Lipid-Induced Integrated Stress Response Onat et al.
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Parkin-deficient BMDMs ( Figure 3J , Online Figure 4K ). Figure 4A ) (33) . No significant differences in plasma glucose and insulin levels or blood cell counts were observed between the groups (Online Figures 5A   and 5B ). We confirmed the inhibitor engaged its molecular target effectively by assessing PERK autophosphorylation and CHOP and ATF3 mRNA ( Figures 4B and 4C , Online Figure 5C ). We detected no improvement in plasma lipids or lipoproteins Figures 1, 2, 3, and 4 .
Continued on the next page
Onat et al. Lipid-Induced Integrated Stress Response (Online Figures 5D-5G) ; however, GSK2606414 led to a significant decrease in atherosclerotic lesions in en face aorta preparations (44%) ( Figure 4D , Online Figure 6A ). GSK2606414 significantly reduced aortic root plaque (32%) ( Figure 4E ) and foam cell area (25%) ( Figure 4F, Online Figure 6B ). No significant changes in the plaque necrotic area or apoptotic cell numbers were noted between the groups (Figure 4G , Online Figure 6C ). There was a reduction in plaque VCAM-1 protein (33%) (Online Figure 6D) , and CCL2 (20%) (Online Figure 6E) , and serum monocyte chemoattractant protein-1 (46%) (Online Figure 6F ) after PERK inhibition, suggesting macrophage recruitment is impacted.
We also analyzed atherosclerosis in the PERK_ASKA, Apoe À/À transgenic mice. These mice Lipid-Induced Integrated Stress Response were fed the Western diet (14 weeks) and treated with 1-NAPP1 (60 mg/kg/day, 4 weeks) ( Figure 4H ). Figure 4I) and CHOP, ATF4, and ATF3 mRNA ( Figure 4J) .
1-NAPP1 inhibited eIF2a phosphorylation (
Although there were no significant differences in systemic metabolic parameters between the groups (Online Figures 7A and 7B ), 1-NAPP1 significantly reduced atherosclerotic lesions in en face aorta preparations (45%) ( Figure 4K) and aortic root foam cell area (20%), but not plaque area ( Figure 4L) . These (34) . We next analyzed the impact of PERK inhibition on plaque cellular composition. GSK2606414 and 1-NAPP1 both lead to significant reduction in P-eIF2a in plaque macrophage-rich areas (GSK2606414: 45%) ( Figure 5A) , (1-NAPP1: 50%) (Online Figure 7C) , as well as CHOP and ATF3 mRNA (GSK2606414: both 33%) ( Figure 4C) , (1-NAPP1: CHOP 50%; ATF3: 48%) ( Figure 4J ). PERK inhibition reduced LONP1 (GSK2606414: 49%) ( Figure 5B ), (GSK2606414: 20%) ( Figure 4C) , and (1-NAPP1: 48%) ( Figure 4J ). Fewer macrophages (GSK2606414: 25%) ( Figure 5C ) (1-NAPP1: 33%) (Online Figure 7D ) and T cells (GSK2606414: 45%) ( Figure 5D ) were observed in plaques, but vascular smooth muscle cells and collagen content were not altered by GSK2606414
( Figures 5E and 5F) . On the basis of these results, the PERK inhibition led to a significant inhibition of hyperlipidemia-induced expression of plaque IL-1b protein (GSK2606414: 45%) ( Figure 5G) , (1-NAPP1: 47%) (Online Figure 7E ), but not IL-1b mRNA ( Figure   5H , Online Figure 7F ). However, PERK inhibition reduced CCL2 and TNFa mRNA levels in plaques (GSK2606414: 20% and 30%, respectively) (Online Figure 6E ) (1-NAPP1: 48% and 47%, respectively) (Online Figure 7G ). PERK inhibition reduced active caspase-1 (both 50%) (GSK2606414: Figure 5I , 1-NAPP1:
Online Figure 7H ). Consistently, PERK inhibitor reduced IL-18 (80%) ( Figure 5J) and IFNg (80%) ( Figure 5J ). BLOCKING THE ISR WITH ISRIB COUNTERACTS ATHEROSCLEROSIS. We next investigated the consequences of modulating eIF2B for atherosclerosis in vivo. Apoe À/À mice on the Western diet (15 to 16 weeks) were injected with ISRIB (1 mg/kg/day; 6 weeks, 2 mg/kg/day; 5 weeks) ( Figure 6A) (35) . ISRIB did not inhibit eIF2a phosphorylation in vivo but reduced CHOP, ATF3, and LONP1 mRNAs ( Figures 6B   and 6C ). There were no significant differences in metabolic parameters or blood cell counts between the groups (Online Figures 8A to 8D) , but ISRIB caused a significant decrease in lesions in en face aorta preparations (1 mg/kg 26% and 2 mg/kg 39%) ( Figure 6D, Online Figure 8E ). ISRIB did not alter plaque area ( Figure 6E ) but reduced aortic root foam cell area (1 mg/kg 28%, 2 mg/kg 32%) ( Figure 6F, Online Figure 8F ). ISRIB also did not alter plaque necrotic area ( Figure 6G) . Figure   7A ) (mRNA: 30%) ( Figure 6C) . ISRIB significantly reduced plaque macrophages and T cells (23% and 45%, respectively) ( Figures 7B and 7C) , IL-1b protein (38%) ( Figure 7D) , but not IL-1b mRNA ( Figure 7E) , and reduced active caspase-1 (50%) ( Figure 7F) . Consistently, ISRIB reduced systemic IL-18 levels (45%) ( Figure 7G) and plaque CCL2 and TNFa mRNA (59% and 58%, respectively) ( Figure 7H) . These collective results demonstrate ISR suppression by ISRIB can mitigate lipid-induced inflammation and plaque development.
DISCUSSION
Persistent PERK activation and eIF2a phosphorylation is observed in atherosclerotic plaques (5, 8) . The targetability of ISR was recently assessed in neurodegenerative diseases, identifying potent and specific Furthermore, yet uncharacterized mitochondria- Lipid-Induced Integrated Stress Response Lipid-Induced Integrated Stress Response driven metabolic shifts driven by ISR inhibitors could alter the immune epigenome. Our results also suggest LONP1 drives sterile inflammation and atherosclerosis, but this possibility needs to be directly tested.
These findings underscore the intricate exchange of information between ER and mitochondria is important for metabolic health and its disruption by dietary fats can promote inflammation and atherosclerosis. Lipid-Induced Integrated Stress Response M A R C H 1 9 , 2 0 1 9 : 1 1 4 9 -6 9
Administration Adverse Event Reporting System). IL-1 receptor (R)-deficient mice (47) The integrated stress response (ISR) controls mitochondrial clearance, mtROS production, and NLRP3 inflammasome activation by lipids. Lipid-induced PERK-eIF2a signaling activates a mitochondrial target, LONP1, which degrades its substrate PINK1 and suppresses Parkin-dependent mitophagy. Inhibition of PERK-eIF2a-LONP1 signaling by small molecules promotes mitophagy and counteracts NLRP3 inflammasome by lipids. mtROS ¼ mitochondrial reactive oxygen species.
chemical chaperones to relieve general ER stress or small molecules targeting one of the proximal regulators in the tripartite UPR signaling (48) . These in vivo studies have taught us lessons about modulating the UPR that were not predictable from cellbased studies. For example, inositol-requiring enzyme-1's (IRE1's) endoribonuclease (RNase) activity has been associated with cell survival as opposed to its kinase activity associated with death (1), but IRE1
RNase inhibitors showed their in vivo antiinflammatory properties are beneficial by mitigating atherosclerosis (7) . Furthermore, in vivo studies with small molecules to modulate key molecular players in the ISR have begun to illuminate how to fine tune this homeostatic response in complex diseases (25, 39, 48) .
In this study, using several different approaches to modulate eIF2a phosphorylation, we demonstrated ISR's causal role in lipid-induced inflammasome activation, inflammation, and atherosclerosis progression. Among these strategies, eIF2B activation (by ISRIB) appears to be the most advantageous in atherosclerosis. First, unlike PERK kinase inhibitors ISRIB is not associated with toxicity. Second, detailed mechanism of how ISRIB impacts translation was recently illuminated (36) . Third, ISRIB's unique memory enhancing effects combined with its anti-inflammatory and anti-atherosclerotic actions suggest targeting eIF2B locus could combat both memory decline and CVD, especially in an aging population (27, 39) . Further studies are needed to illuminate ISRIB's impact on aging, but the available information on the specificity, efficacy, and mechanism of action of ISRIB suggest eIF2B could be a desirable, molecular target for the modulation of the ISR in atherosclerosis (26, 39, 40) . Lipid-Induced Integrated Stress Response M A R C H 1 9 , 2 0 1 9 : 1 1 4 9 -6 9
